AMNOG Benefit Assessment

We analyzed the outcomes of previous AMNOG BENEFIT ASSESSMENTS to enable our pharma clients to improve their Market Access and Reimbursement planning.

The benefit assessment of pharmaceuticals in accordance with the German Social Code, Book Five (SGB V), section 35a

This page compiles information on the benefit assessment of pharmaceuticals in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG).

With the AMNOG BENEFIT ASSESSMENT analysis we developed a tool where you can see the outcomes of the benefit assessment at a glance.

We analyzed and compared the additional benefit that was recommended by the Institute for Quality and Efficiency in Health Care (IQWiG) and then assessed by the Federal Joint Committee (G-BA) with the expectations of the manufacturers.

Please find here our analysis focusing on

You can request a download of the entire analysis free of charge. Get in touch!